Oppenheimer analyst Steven Lichtman reiterated a Buy rating on Organogenesis Holdings (NASDAQ:ORGO) Inc on Monday, setting a price target of $28, which is approximately 32.39% above the present share price of $21.15.
Lichtman expects Organogenesis Holdings Inc to post earnings per share (EPS) of $0.16 for the second quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Organogenesis Holdings, with an average price target of $24.5.
The analysts price targets range from a high of $28 to a low of $21.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $106.81 million and a net profit of $21.77 million. The company's market cap is $2.71 billion.
According to TipRanks.com, Oppenheimer analyst Steven Lichtman is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.7% and a 57.44% success rate.
Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.